Abeona Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company focused on developing and delivering innovative cell and gene therapies for life-threatening rare genetic diseases. The company's flagship product is ZEVASKYN (prademagene zamikeracel, or pz-cel), an autologous, cell-based gene therapy approved by the FDA in April 2025 for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe and painful genetic skin disorder. Abeona's proprietary AIM vector platform also powers a preclinical and clinical pipeline of adeno-associated virus (AAV)-based gene therapies targeting ophthalmic diseases, including ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercializing and scaling ZEVASKYN (prademagene zamikeracel), the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds. This includes expanding the Qualified Treatment Center (QTC) network and optimizing the patient journey to 90 days.
Expected impact: Drive product revenue growth, expand patient access, and establish a steady cadence of biopsies and treatments to achieve profitability.
Prioritizing the development of ABO-701 (PSMA SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA for advanced prostate cancer, while deprioritizing in-house genetic eye disease programs.
Expected impact: Establish a high-value oncology franchise targeting solid tumors with well-defined clinical endpoints and a large market size.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured exclusive rights to the Synthetic Immune Receptor (SIR-T™) platform targeting PSMA, enabling the development of ABO-701 for advanced prostate cancer.
Terms: $7.0 million upfront payment made in the first quarter of 2026.
Beacon exercised its option for a worldwide, non-exclusive license to use Abeona's novel AIM capsid AAV204 for up to five gene or disease targets in ophthalmology.
Terms: Abeona is eligible to receive clinical, regulatory, and sales-based milestones and royalties.
Sublicense for Rett syndrome gene therapy programs (TSHA-102 and TSHA-118).
Terms: Abeona received a clinical milestone payment in 2025 and remains eligible for future clinical, regulatory, and sales-based milestones and royalties.